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Abstract
Rhodamine 123 has been shown to be a substrate for P-glycoprotein in multidrug resistant cells, In the present investigation the 
disposition of rhodamine 123 was studied in the isolated perfused rat kidney, After exposing the kidneys to perfusate concentrations 
ranging from 10 to 1000 ng/m l, the renal clearance was 4-1 times the clearance by glomerular filtration, respectively, indicating active 
and saturable secretion of rhodamine 123. The rate-limiting step in secretion was found to be membrane passage from cell to tubular 
lumen. Suprisingly, renal clearance was not influenced by the P-glycoprotein inhibitors cyclosporin A or digoxin. However, pretreatment 
o f  the kidneys with verapamil and quinidine (inhibitors of both P-glycoprotein and organic cation transport) or cimetidine (organic cation 
transport inhibitor) resulted in a significantly reduced rhodamine 123 clearance, indicating that the renal organic cation carrier may be 
involved in active secretion. Rhodamine 123 accumulated extensively in the isolated perfused rat kidney; tissue concentrations of 
270 -360  times the perfusate concentration were determined. Similar accumulation ratios at different perfusate concentrations were found, 
suggesting that the compound enters the tubular cells by (facilitated) diffusion. In conclusion, rhodamine 123 accumulated extensively in 
the isolated perfused rat kidney and active renal secretion appears to be pi*eferentially mediated by the organic cation carrier and not by 
P-glycoprotein.
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1. Introduction
Resistance to various chemotherapeutic drugs is a phe­
nomenon often observed in patients and cell cultures. Drug 
resistance associated with the overexpression of the mul­
tidrug resistance-1 gene, which encodes the P-glycoprotein 
or multidrug transport protein, is characterized by a re­
duced intracellular drug accumulation and increased cellu­
lar drug efflux. P-glycoprotein is an ATP-dependent inte­
gral membrane protein, which is not only expressed in 
resistant tumor cells, but also in normal tissues such as 
liver, intestine, adrenal gland, placenta and kidney. The 
physiological function of P-glycoprotein is not clear, but 
its apical distribution in secretory epithelia and role in drug 
efflux suggest that P-glycoprotein may function in the 
excretion of endogenous compounds and naturally occur­
ring toxins (Ford and Hait, 1990; Thibaut et al., 1987;
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Gottesman and Pastan, 1993; Leveille-Webster and Arias, 
1995; Al-Awqati, 1995). Physiological substrates for P- 
glycoprotein are cortisol, dexamethasone and aldosterone, 
whereas progesterone is a potent inhibitor of P-glyco­
protein-mediated transport (Ichikawa-Haraguchi et al., 
1993; Ueda et al., 1992). Other substrates for P-glyco­
protein are anthracylines, vinca alkaloids, epipodophyllo- 
toxins, taxol, actinomycin D (Ford and Hait, 1990). Fur­
thermore, the widely used cardiac glycoside, digoxin, is 
actively secreted into urine by P-glycoprotein in the kidney 
(De Lannoy et al., 1992; Hori et a l ,  1993),
The ability to excrete these substrates can be reduced by 
treatment with chemosensitizers, compounds that reverse 
or antagonize multidrug resistance. The group of inhibitors 
consists of a wide variety of structurally unrelated drugs, 
including calcium channel blockers, hormones and steroids, 
hydrophobic peptides, cyclosporins, calmodulin antago­
nists, and miscellaneous hydrophobic cationic drugs, It is 
suggested that the interaction between substrates and in­
hibitors is related to a common binding site on P-glyco­
protein. Resistance reversal by cyclosporin A may in part
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also be due to competition for transport. ATP binding is 
not blocked by any of the reversal agents, indicating 
separate ATP and drug binding sites on P-glycoprotein 
(Ford and Hait, 1990; Gottesman and Pastan, 1993; Lev- 
eille-Webster and Arias, 1995).
The proximal tubule of the kidney is the most important 
site in active renal drug elimination, and proximal tubular 
cells contain separate systems for organic anions and 
cations. The active step in the secretion of organic anions 
is located at the basolateral membrane, and that of organic 
cations at the luminal membrane (Pritchard and Miller,
1993). In addition, P-glycoprotein is also present at the 
luminal membrane (Lieberman et al., 1989). Several hy­
drophobic amines known to interact with the classical 
organic cation transport system, for example verapamil, 
quinine, quinidine, and quinacrine, inhibit P-glycoprotein- 
mediated transport. For this reason P-glycoprotein was 
suggested to be an unidentified component of the renal 
organic cation carrier, however, photoaffinity labeling 
studies implied that separate carrier systems exist (Holo- 
han et al., 1992). More recently, it was shown in a 
functional expression system in Xenopits laevis oocytes, 
that P-glycoprotein and the organic cation earner are in­
deed different transport proteins (Nelson et al., 1995).
In the present investigation the transport mechanisms of 
rhodamine 123 and the interaction with various cationic 
drugs were studied in the isolated perfused rat kidney. This 
in vitro technique has been shown useful for the investiga­
tion of renal organic anionic and cationic drug excretion 
(Cox et al., 1990; Boom et aL, 1994). Previous investiga­
tions in various carcinoma cells showed that the mitochon­
drial dye with anticarcinoma activity, rhodamine 123 
(Bernal et al., 1983), is effectively pumped out of these 
cells via P-glycoprotein (Neyfakh et al., 1989; Lee et al., 
1994; Denis-Gay et al., 1995). More recently, rhodamine 
123 resistance was found to be related to the expression of 
the mdrl gene in a monkey kidney epithelial cell line, 
although direct evidence that rhodamine 123 is transported 
by P-glycoprotein in this cell line was not obtained 
(Brouty-Boye et a l ,  1995). Rhodamine 123 is not in use as 
a drug, but because of its excellent fluorescent properties 
and transport characteristics it is a potential model com­
pound for studying P-glycoprotein-mediated transport in 
the kidney and other organs. Aim of our study was to 
investigate the role of P-glycoprotein as a drug transport 
system in the isolated perfused rat kidney.
2. Materials and methods
2.7. Methods
2 J J .  Kidney isolation and perfusion
The isolation and perfusion of the rat kidney and stabil­
ity of the perfused kidney system were described in detail 
previously (Cox et al., 1990). Briefly, male Wistar-Han-
nover rats (225-275 g) were anesthetized intraperitoneally 
with pentobarbital (6 mg / 100 g) and furosemide was 
injected intraperitoneally (1 mg / 100 g) to prevent deterio­
ration of the distal nephron. Heparin (125 I.U ./100 g) was 
injected via the femoral vein. The ureter of the right 
kidney was cannulated and the renal artery via the mesen­
teric artery without interruption of the blood flow. The 
kidney was then excised and placed in a fluid bath with a 
constant temperature of 37.5°C. The perfusion fluid had 
the following composition (mM, except where indicated 
otherwise): NaCl 114.0, KC1 5.2, CaCl2 1.8, MgCU 1.0, 
N aH C 03 22.5, N a2H P 0 4 0.84, K H 2P 0 4 0.28, glucose
5.0, urea 4.0, pluronic F108 25.0 g /I ,  glutathione 0.33, 
inositol 0.083, cysteine 0.50, glycine 2.3, Na-pyruvate 2.0, 
Na-acetate 1.22, Na-propionate 0.21, inosine 1.0, alanine
5.0, glutamine 0.11, L-glutamic acid 2.0, a-ketoglutarate 
1.15, ascorbic acid 0.01, Na-lactate 1.0, choline chloride
1.0 mg/1, insulin 4 I .U ./l ,  aldosterone 2.0 fig/1, lysine- 
vasopressin 0.01 I .U ./l ,  and angiotensin II 15.0 ng/1. To 
this solution 1.0% Synthamin 14, a mixture of 15 amino 
acids, was added. Pluronic F-108 was used as oncotic 
agent in the albumin-free perfusion fluid. For the determi­
nation of glomerular filtration rate, inulin was added to the 
perfusion fluid (100 |j,g /m l).
2.7.2. Clearance experiments
In our perfused kidney preparation, perfusion medium 
was recirculated at a constant flow rate with a perfusate 
pressure of approximately 90 mmHg. During the first 5 
min of perfusion, the venous effluent was discarded and 
after this period the perfusion fluid was recirculated and 
the kidney was allowed to stabilize for 30 min. Then the 
experiment was started with a 30 min baseline period, after 
which rhodamine 123 was administered. During the base­
line period the perfusate volume was 500 ml from which a 
sample of 5 ml was drawn. After the baseline period, the 
experimental fluid was connected to the kidney, with a 
total volume of 150 ml in which rhodamine 123 was 
already dissolved. The experimental period was 120 min. 
Doses added to the perfused kidneys were 0 (time con­
trols), 1.5, 15, 52,5 and 150 jig of rhodamine 123, result­
ing in initial perfusate concentrations of 0, 10, 100, 350 
and 1000 ng /m l. The influence on rhodamine 123 clear­
ance of the following compounds were studied: cy­
closporin A and digoxin (P-glycoprotein-inhibitors), vera­
pamil and quinidine (organic cation transport and P-glyco­
protein inhibitors), and cimetidine (organic cation transport 
inhibitor). All inhibitory agents were added to the isolated 
perfused rat kidney at the start of the baseline period, and 
remained in perfusion fluid during the experimental period. 
Urine samples were collected during control and experi­
mental periods over 10 min intervals. Perfusate samples 
(500 |jl1) were drawn at the midpoint of each urine collec­
tion interval. Two additional perfusate samples were taken, 
one at the beginning of the experimental period ( / =  0), 
and one at the end of the experiment. At the end of the
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experiment the kidney was removed from the system, 
blotted, weighed, and frozen until analysis. Urine and 
perfusate samples were stored at — 20°C until analysis. 
Perfusion fluid during experimental period, and perfusion 
an d  urine samples were protected from light.
2 ,1 3 . Preload experiments
Kidneys were isolated and perfused in a similar way as 
described above for the clearance experiments, except for 
th e  experimental period. The 30 min baseline period was 
followed by a 60 min preload period, in which 150 jxg 
rhodamine 123 was added to perfusion medium (150 ml). 
Subsequently an efflux period was studied for 90 min, at 
w hich  kidneys were perfused with clean perfusion fluid 
(1000  ml) without recirculation. After 40 min of efflux a 
urinary flow change from 60 to 16 jxl/min was induced 
b y  changing the perfusate flow rate from 16 to 11 m l/min. 
W henever verapamil was used to inhibit rhodamine 123 
transport, this agent was added to perfusion fluid at the 
start of the baseline period and remained in perfusion fluid 
during the preload and efflux period. Urine samples were 
collected during all periods over 10 min intervals. Per­
fusate samples (400 jjl! )  were drawn at the beginning and 
after 5, 15, 35, 55 and 60 min of the preload period. 
D uring the single-pass efflux period, samples of 600 p,l 
w ere drawn from the perfusion fluid every 5 min, and one 
a t  the end of the efflux period. Perfusate and urine sam­
ples, and kidneys were handled as described for the clear­
ance experiments,
2.1 .4 . Analysis
Urine and perfusate samples were analyzed for glucose 
and various electrolytes as described previously (Cox et 
al., 1990). Inulin was determined according to a previously 
published method (Heyrovski, 1956). The concentration of 
rhodamine 123 in perfusate, urine and kidney samples was 
determined by means of fluorescence spectrophotometry. 
To this end, an aliquot of 2-200 |xl of the perfusate 
sample or 0.5-20 jxl of the urine samples was taken and 
adjusted to 600 jxl with analysis buffer (0.01 M KH2P 0 4, 
pH 2.6), and fluorescence was measured using a Perkin 
Elmer LS50 luminescence spectrophotometer (Perkin 
Elmer, Beaconsfield, Buckinghamshire, UK). The excita­
tion wavelength was set to 501 nm, the emission wave­
length to 531 nm and for both wavelengths a slit width of 
5 nm was used. Concentrations were calculated by compar­
ing fluorescence intensity (in photomultiplier units) with a 
calibration curve of spiked samples of blank perfusion 
fluid with different concentrations of rhodamine 123. The 
concentration of rhodamine 123 in kidney tissue was deter­
mined similarly. The kidneys were homogenized in 5 ml 
distilled water with a Polytron homogenizer (Braun Mel- 
sungen, Germany) on setting 10 for 2 times 60 s. Subse­
quently, to 50 (jl I  of the kidney homogenate 250 (jl I  
acetonitrile was added, vortexed and centrifuged for 10 
min at 2000 X g. Of the supernatant, an aliquot of 200 jjlI
was added to ice-cold glass tubes and evaporated until 
dryness. The residue was dissolved in 600 jutl analysis 
buffer, either undiluted or 10-50 times diluted (dependent 
on the expected concentration), and fluorescence intensi­
ties of triplicate samples was measured and averaged. 
Concentrations were calculated by comparing fluorescence 
intensity with a calibration curve of spiked samples of
blank kidney homogenates with various concentrations of
i
rhodamine 123. Linear calibration curves were obtained in 
all cases ( r 2 >  0.998). Rhodamine 123 did not bind to 
pluronic F-108. This was checked by means of ultrafiltra­
tion using YM-10 membranes with a molecular weight 
cut-off of 10000 in the MPS-1 micropartition system 
(Amicon, Grace B.V., Dronten, Netherlands),
2.1.5. Data analysis
All data are expressed as means ±  S,D. Statistical dif­
ferences between means were determined with one-way 
analysis of variance followed by the least significant dif­
ference test for comparison of multiple means. Differences 
were considered significant if P < 0.05. The concentration 
of rhodamine 123 in kidney tissue (CT) was expressed as 
the amount of drug per weight of tissue.
2,2. Materials
Sodium pentobarbital was obtained from Apharmo 
(Arnhem, Netherlands). Heparin, aldosterone and inulin 
were from Organon (Oss, Netherlands). Rhodamine 123 
was purchased from ICN (Costa Mesa, CA, USA), lysine- 
vasopressin from Sandoz Pharma (Basel, Switzerland), 
angiotensin II from Beckman (Palo Alto, CA, USA) and 
Synthamin 14 was from Travenol (Thetford, Norfolk, UK). 
Cyclosporin A was kindly provided by Sandoz Pharma 
(Basel, Switzerland) and Pluronic F-108 was obtained 
from BASF (Arnhem, Netherlands). All other chemicals 
were of analytical grade and obtained either from Sigma 
(St. Louis, MO, USA) or Merck AG (Darmstadt, Ger­
many). A stock solution of cyclosporin A was prepared in 
DMSO (20 m g/m l).
3. Results
3.1 . Effect on kidney function
The mean values for the functional parameters of base­
line period ( — 3 0 -0  min) of all isolated perfused rat 
kidney experiments are presented in Table 1. The control 
values (first data column) represent mean values of all 
experiments in which rhodamine 123 was added solely to 
the perfused kidney system. The other columns show data 
of the functional parameters after pretreatment of the 
kidneys with verapamil, cimetidine, cyclosporin A, quini- 
dine or digoxin. Although some parameters were slightly 
changed after pretreatment with one of the inhibitory
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Table 1
Experimental conditions of the isolated perfused rat kidney in baseline period, without or with pretreatment with verapamil a
Functional parameter Control Verapamil 









PEjlucose W 0.84 +  0.31 0.46 ± 0 .1 3  b 0.87 ±  0.74 1.5 ± 0 .8 1.3 ± 0 .6 1.4 ± 0 .2  b 1.5 ±  1.0
FEsodiom (%) 1.8 ±  0.4 1.8 ± 0.8 2.6 ±  1.9 2.2 ±  0.7 2.5 ±0 .1  b 2.1 ± 0.8 2.5 ±  0.9
GFR (|xl/min) 530 ±  80 540 ±  100 520 ±  70 468 ±  34 422 ±  44 445 ±  53 458 ±  128
Urinary flow (fxl/min) 25 ± 4 25 ± 2 25 ± 4 26 ±  1 24 ± 3 23 ± 2 24 ±  3
Urinary pH 5.5 ±  0.2 5.6 ±  0.3 5.5 ± 0 .2 5.8 ±  0.4 5.5 ±0 .1 5.5 ±0.1 5.8 ±0 .2  b
RPP (mmHg) 94 ±  11 95 ± 7 90 ±  10 105 ±  10 105 ± 7 89 ± 2 100 ±  10
FR water W 95 ±  1 95 ±  1 95 ± 2 94 ±  1 94.2 ±0 .1 95 ±  I 95 ±  1
Perfusate flow (m l/m in) 13 +  3 14 ± 2 12 ±  2 12 ±  2 16 ± 5 13 ± 2 13 ±  2
n 16 8 8 6 3 3 4
a Means ±  S.D. FE =  fractional excretion* FR =  fractional reabsorption, RPP =  renal perfusion pressure. P < 0.05: significantly different from control 
value.
agents, no severe effects on kidney functioning could be 
determined. In agreement with previous investigations (Cox 
et al,, 1990), the system remained stable and viable during 
the whole experimental period. Addition of rhodamine 123 
slightly increased renal functioning as compared to control 
experiments, which could be concluded from a slightly 
decreased fractional excretion of sodium, calcium and 
glucose throughout the whole experimental period ( P  <
0.05).
3.2. Renal handling
Rhodamine 123 was cleared very rapidly from per­
fusate. Fig. 1 shows the perfusate concentration and corre­
sponding excretion rate data as a function of time. Bipha- 
sic perfusate concentration-time curves were obtained, with 
initially a rapid decline (50% of the amount rhodamine 
123 was cleared after 35 min of perfusion), and subse­
quently a virtual infinite terminal phase. The urinary excre­
tion rate increased slowly after addition of rhodamine 123, 
a maximum rate was achieved after 40-50  min followed 
by a gradual decrease. Within the perfusate concentration 
range, the renal clearance was 1-4 times higher than the 
clearance by glomerular filtration (renal fractional clear­
ance or C1R/ G F >  1), indicating active secretion of rho­
damine 123 (Fig. 2A). Surprisingly, the renal clearance of 
rhodamine 123 (at a dose of 1.5 jxg) was not affected by 
the P-glycoprotein inhibitors, cyclosporin A (5 juig/ml) 
and digoxin (10 (ljlM ) (Fig. 2B). However, pretreatment of 
the kidneys with cimetidine (10 |jlM) and quinidine (6 
|xM) resulted in a significant reduction in renal rhodamine 
123 clearance. Treatment with 10 or 50 |jlM verapamil 
also resulted in a significantly decreased renal clearance of 
rhodamine 123 (Fig. 2C). None of the inhibitors had an 
effect on the perfusate concentration-time profiles of rho­
damine 123, suggesting that transport from perfusion fluid 
into the tubular cells was unaffected. Treatment with 50 
[xM verapamil resulted in a C1R/G F  < 1, suggesting that a
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Fig. 1. Rhodamine 123 perfusate concentration (left panel) and urinary excretion rate (right panel), as a function of time. Doses added to the perfused 
kidneys were 1.5 (▼); 1 5 (B ) ;  52.5 ( a ) and 150 jjLg ( • ) .  All data points are means ±  S.D. of four experiments.
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Fig. 2< Renal fractional clearance (C1R /G F )  as a function of time. (Panel 
A )  Four different doses of rhodamine 123 were studied (>2 = 4 for each 
dose). Doses added to the perfused kidneys were 1.5 (▼); 15 (■ ); 52.5 
( a )  and 150 (xg ( • ) .  (Panel B) A dose of 1.5 |xg was studied ( y ,  
«  =  4), and after preincubation with 10 |xM cimetidine, CM ( + ,  n ~  6), 5 
fjLg/m] cyclosporin A, CSA (O , =  3), 10 p,M digoxin, DGX ( □ ,  
N  =  4) and 5 /Ag/ml quinidine, QD ( a , n =  3), (Panel C) A dose of 1.5 
jjtg rhodamine was used alone (▼, n =  4), and after preincubation with 
.10 ( v ,  /7 =  4) or 50 jjlM verapamil, VP ( v ,  » — 4), Mean values are 
presented. For the sake of clarity standard deviations were omitted from 
Ihis figure, but varied between 8 and 40% for the different doses 
rhodamine. For the pretreated kidneys standard deviations varied between 
14 and 38% for cimetidine and quinidine» between 38 and 67% for 
cyclosporin A and digoxin, and between 4 and 26% for verapamil.
reabsorptive mechanism is also involved in the overall 
renal clearance of rhodamine 123.
To further investigate renal excretion and reabsorption 
of rhodamine 123, preload experiments were performed. In 
these experiments, the perfused kidneys were exposed to 
150 jxg rhodamine 123 for 60 min, after which the kidneys 
were connected to clean perfusion fluid. Functional param­
eters of the perfused kidneys in preload experiments were 
not different from the parameters in normal clearance
experiments (data not shown). In order to determine the 
mechanism of reabsorption for rhodamine 123 found after 
pretreatment with 50 jxM verapamil, urine flow was 
changed after preloading the kidneys. Fig. 3 presents the 
curves of the perfusate rate and renal excretion rate of 
rhodamine 123 as a function of time, with and without 
pretreatment of the kidneys with 50 jjlM verapamil. Evi­
dently, a certain amount of rhodamine 123 is transported 
back from tubular cells to the perfusion fluid (upper 
panel), and a urinary flow change from 60 to 16 fxl/min 
hardly affected this transport (A versus B). Verapamil (50 
|xM) significantly reduced rhodamine 123 transport back 
into the perfusion medium. The renal excretion rate after 
preloading the kidneys with rhodamine 123 decreased with 
the urine flow, indicating that passive back-diffusion prob­
ably accounts for the reabsorptive mechanism found ear­
lier. At a urinary flow of 16 jxl/m in, a renal excretion rate 
of 118 ±  18 n g /m in  was found (Fig. 3, lower panel, B), 
which is very similar to the renal excretion rate of rho­
damine 123 after addition of 150 jxg in the normal clear­
ance experiments (103 ±  12 ng /m in , Fig. 1). This sug­
gests that in the overall renal clearance of rhodamine 123 
membrane passage from cell to tubular lumen is the rate- 
limiting step in secretion. Pretreatment of the perfused
Perfusate excretion rate 
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600  - 
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Fig. 3. Rate o f  transport back into the perfusate (perfusate excretion rate) 
and renal excretion rate after preloading perfused kidneys with 150 p-g 
rhodamine 123. Preload experiments were done as described in detail in 
Section 2. Closed circles represent data with rhodamine 123 alone, open 
circles are data after pretreatment with 50 jjlM verapamil. During the first 
40 min of the efflux period, the urinary flow was 60 |x l/m in (A), 
whereafter the flow was reduced to 16 jx l/m in  (B). All data points are 
means ±SJD . of three experiments.
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Amount in kidney tissue 
(jjg/g kidney)
Time (min)
Fig. 4. Calculated amount of rhodamine 123 per weight of kidney as a 
function of time. Four different doses were added to the perfused rat 
kidneys: 1.5 pg (▼ ); 15 jxg ( H ); 52.5 |xg ( A ) and 150 p,g ( ® ). All data 
points are means+ S.D. of four experiments.
kidneys with verapamil resulted in significantly lower 
excretion rates, which were also similar to the rates ob­
tained in the normal clearance experiments in presence of 
50 |xM verapamil. Rhodamine 123 excretion rates were 
41 + 6 and 27 ±  6 for preload and normal clearance exper­
iments, respectively, which corresponded with a reduction 
in renal clearance of approximately 70%.
3.3. Renal accumulation
The rapid disappearance from perfusion fluid and the 
delayed appearance in urine of rhodamine 123, indicate 
that the compound is retained by the tubular cells. In Fig. 
4, the concentration of rhodamine 123 in the kidney, 
expressed as the amount of drug per weight of tissue, is 
plotted as a function of time. For every time point, the 
concentration was estimated by subtracting the amount in 
perfusate and the amount excreted in urine at time t from 
the total amount added to perfusate at time 0. Actual 
kidney tissue concentrations were determined at the end of
Table 3
Dose-dependent accumulation of rhodamine 123 in the isolated perfused 
rut kidney a





15 5 .0±1 .2 350+140 4
52.5 17+1 270 +  60 4
150 52 +  8 360+100 4
150 +  VP10 b 64 +  28 350 ±180 4
150 + VP50 c 57 +  5 350 ± 5 0 4
d Mean data±S.D . are presented. Measurements as described in Section 
2, In the presence of b 10 verapamil and L 50 jjlM verapamil; n 
represents the number of perfused kidneys used.
the experiments and presented in Tables 2 and 3. For every 
rhodamine 123 dose, the tissue concentration is 30-40% 
lower than the estimated concentration after 120 min of 
perfusion. Probably because of an extensive intracellular 
binding we were not able to recover 100% of the theoreti­
cally calculated concentration in kidney tissue (Fig. 4). 
Furthermore, the accumulation ratios are given, which 
were obtained by dividing the concentration in kidney 
tissue by the concentration at the end of the experiment 
(Tables 2 and 3), Between the doses, similar accumulation 
ratios were found. Treatment with cimetidine and quini- 
dine significantly enhanced the cellular rhodamine 123 
uptake.
4. Discussion
The kidneys used in this study showed a good renal 
functioning, and were stable for at least 2 h. Surprisingly, 
the fractional excretion (%) of sodium, calcium and glu­
cose decreased after addition of rhodamine 123, indicating 
that kidney viability increased as compared to control 
experiments. This is in contrast with several in vitro 
investigations showing that rhodamine 123 possesses a 
cytotoxic potential, including uncoupling of oxidative 
phosphorylation and mitochondrial swelling (Bernal et aL, 
1983; Emaus et al., 1986; Lampidis et al., 1983). The 
reason that we did not find a decrease in renal function is
Table 2
Effect of various drugs on the accumulation of rhodamine 123 in the isolated perfused rat kidney a
Treatment Amount in kidney Kidney/perfusate
ratio
n
Control (dose = 1.5 |xg) 0.53 ±  0.06 350 ±  50 4
+  VP10 h 0.57 ±  0.05 3 4 0 ±  50 4
+  VP50 c 0.60 ±  0.03 3 9 0 ±  80 4
+  CM10 d 0.85 ± 0 .1 3  h 470 ±  160 6
+  DGX10 B 0.56 ±  0.05 490 ±  270 4
+  CSA6 f 0.41 ± 0 .3 0 330 ±  170 3
+  QD6 8 0.67 ±  0.07 750 ±  70 h 3
a Mean data ±  S.D. are presented. Measurements as described in Section 2. In the presence of b 10 jjlM verapamil, c 50 jxM verapamil, d 10 |jlM 
cimetidine, e 10 |xM digoxin, f 6 |jlM  cyclosporin A and g 6 jjlM quinidine. h P < 0.05: significantly different from the same dose without treatment; n 
represents the number of perfused kidneys used.
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most likely a result of the low concentrations we used; 
perfusate concentrations were between 25 nM and 2.5 jjlM. 
At these concentrations other investigators also found little 
o r no toxic effects for rhodamine 123 (Emaus et al., 1986). 
However, we have no explanation for the slight increase in 
proximal tubular function observed in the present study. 
Kidney functional parameters were hardly changed due to 
the presence of verapamil, cimetidine, cyclosporin A, 
quinidine or digoxin in perfusion fluid. In contrast with the 
known renal effects of verapamil (Chan and Schrier, 1990), 
the fractional excretion of calcium and glomerular filtra­
tion rate were not enhanced in the isolated perfused rat 
kidney, which can be explained by the fact that blood 
vessels are maximally dilated in this preparation.
Our clearance experiments demonstrate that the cationic 
drug, rhodamine 123, is efficiently secreted by the per­
fused kidney in a dose-dependent manner. Fig. 2 shows 
that the C1r / G F  of the lowest dose is significantly higher 
than that for the highest dose (3.1 ± 0 .5  vs. 1.6 ± 0 .2 ;  
P  <  0.01), indicating active, saturable secretion. However, 
it is unlikely that P-glycoprotein is involved. Cyclosporin 
A, a potent P-glycoprotein inhibitor, which has been shown 
to inhibit rhodamine 123 efflux in multidrug resistant cells 
(Lee et al., 1994) and in the isolated perfused rat liver 
(Stapf et al., 1994), failed to reduce the renal excretion of 
the compound in the isolated perfused rat kidney. Further­
more, digoxin, a substrate for P-glycoprotein, was not able 
to affect rhodamine 123 transport either, Two other P- 
glycoprotein inhibitors, verapamil and quinidine, signifi­
cantly reduced renal rhodamine 123 clearance, however, 
this effect is probably related to the organic cation carrier 
of which both compounds are also known to be good 
inhibitors (Pritchard and Miller, 1993). Supporting evi­
dence is given by cimetidine, an effective inhibitor of the 
organic cation carrier (Somogoyi, 1987; Boom et al.,
1992), which reduced the renal rhodamine 123 clearance 
by as much as 70%. It was recently speculated that cimeti­
dine might also be a substrate for P-glycoprotein, because 
in a distal tubule derived epithelial cell line (Madin-Darby 
canine kidney cells) transfected with human P-glyco­
protein an increased capacity for cimetidine transport from 
basolateral to luminal membrane was observed (Pan et al.,
1994). However, in the same model it was also shown that 
cimetidine was not able to inhibit transport of P-glyco­
protein substrates. Additionally, cimetidine had no effect 
on the P-glycoprotein-mediated biliary excretion and dis­
position of cyclosporin A (Hughes et al., 1995), an in­
hibitor as well as a substrate for P-glycoprotein (Saeki et 
al., 1993). Therefore, we believe that the inhibitory po­
tency of cimetidine is related to inhibition of the organic 
cation system, although the involvement of P-glyco- 
protein-mediated transport in overall renal rhodamine 123 
excretion can not be ruled out completely, because both 
transport systems exhibit overlapping substrate specifici­
ties (Ford and Hait, 1990). A recent study with dauno- 
mycin in renal proximal tubules of killifish revealed that
P-glycoprotein and the organic cation system may provide 
parallel excretory pathways for drugs in the kidney (Miller,
1995).
Organic cation transport in renal proximal tubules in­
volves entry into the tubular cell by (facilitated) diffusion, 
for which the potential difference over the basolateral 
membrane of —60 to —80 mV is the driving force 
(Pritchard and Miller, 1993). Although the contribution of 
a nonsaturable active uptake mechanism for rhodamine 
123 into proximal tubular cells can not be ruled out 
completely, the similar accumulation ratios at different 
perfusate concentrations and the lack of an effect o f any of 
the inhibitory agents on the perfusate concentration-time 
curves suggest that the compound enters the cells by 
(facilitated) diffusion. After preloading the kidneys with a 
high dose o f rhodamine 123, a substantial amount of the 
drug was transported back into the perfusion fluid, suggest­
ing that the basolateral organic cation carrier is bidirec­
tional and driven by the concentration gradient. Verapamil 
significantly reduced rhodamine 123 back-flux by about 
50%, indicating that this transport is specific. These two 
properties are in agreement with the characteristics found 
for facilitated diffusion, as has been described for the 
basolateral organic cation system.
The next step in proximal tubular secretion is transport 
into the luminal compartment. For organic cations this step 
is active and in exchange for protons (Pritchard and Miller,
1993). Since neither one of the inhibitors affected the 
plasma concentration-time curves, active secretion may be 
considered to take place at the luminal membrane. An 
important finding in the characterization of the overall 
excretion of rhodamine 123 is that the rate-limiting step in 
secretion is transport from tubular cells into the luminal 
compartment. Pietruck and Ullrich (1995) showed previ­
ously that rhodamine 123 exhibits affinity for the renal 
organic cation system, but to a higher extent for the 
luminal carrier in comparison to the basolateral carrier. 
Furthermore, they also observed a net reabsorption in their 
in situ perfused rat kidney preparation, but in contrast to 
our results they suggested that reabsorption is an active 
mechanism. The preload experiments in our study revealed 
that reabsorption is a passive process.
Because perfusate clearance was initially very rapid and 
urinary excretion delayed, a substantial amount of rho­
damine 123 must be retained by the tubular cells. We were 
able to estimate the amount accumulated in kidney tissue 
accurately in the course of the experiment. The extensive 
accumulation found for rhodamine 123 in the isolated 
perfused rat kidney, with tissue-to-medium concentrations 
up to 360, can not be simply explained by uptake driven 
by the electrochemical gradient, which is the mechanism 
for basolateral entry of organic cations. The similar accu­
mulation ratios at different perfusate concentrations may 
signify that uptake of rhodamine 123 is not mediated by an 
active mechanism, which is able to transport the organic 
cation to levels above its electrochemical gradient. There­
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fore, the drug is most likely subject to intracellular seques­
tration. In addition, the biphasic profile of the perfusate 
concentration-time curves suggests the existence of an 
intracellular compartment in the renal handling of rho- 
damine 123. Earlier reports showed that rhodamine 123 
accumulates specifically in mitochondria (Bernal et al., 
1983; Emaus et al., 1986), probably driven by the inside 
negative membrane potential of these organelles ( — 220 
mV), Preliminary uptake experiments in isolated proximal 
tubular cells of the rat kidney using confocal microscopy, 
demonstrated that intracellular accumulation may include 
more than ju s t m itochondria l com partm entation  
(Masereeuw et al., unpublished findings). Additional or- 
ganellar compartments that sequester this cationic dye may 
be endosomes, lysosomes and Golgi vesicles. These or­
ganelles are more acidic than the surrounding cytoplasm, 
and the inside negative pH gradient may drive organic 
cation uptake (Mellman et al., 1986). A recent study on 
tetra-ethylammonium accumulation in rat kidney cortex 
endosomal vesicles showed that uptake is specific, ATP- 
dependent, and driven by a pH-gradient (Pritchard et al.,
1994), Whether or not such a specific sequestration mecha­
nism is involved in rhodamine 123 accumulation remains 
to be determined.
Significant enhancement of rhodamine 123 accumula­
tion in the perfused kidney was found for cimetidine and 
quinidine, probably due to inhibition of the cation system 
at the luminal membrane. For cimetidine it has been 
reported that this cationic drug exhibits a higher affinity 
for the luminal transporter than for the basolateral system 
(Pietruck and Ullrich, 1995), and possesses also a higher 
inhibitory potency against the luminal system (Boom et al,, 
1992). Less clear is why verapamil did not reduce the renal 
accumulation of rhodamine 123. An explanation may be 
that verapamil reduced both influx and efflux of the or­
ganic cation. Supporting evidence is given by the preload 
experiments in which verapamil was able to affect the 
back-flux of rhodamine 123 into perfusion medium by 
inhibition of the basolateral system.
In summary, rhodamine 123 is actively secreted in the 
isolated perfused rat kidney. Transport across the luminal 
membrane into the tubular urine was found to be the 
rate-limiting step in overall excretion. Renal clearance was 
susceptible to inhibition by cimetidine, quinidine and vera­
pamil, but not to cyclosporin A and digoxin. These obser­
vations suggest that rhodamine 123 is predominantly se­
creted by the organic cation transport system in the iso­
lated perfused rat kidney, and that P-glycoprotein transport 
plays a minor role.
Acknowledgements
This study was supported by a grant from the Dutch 
Kidney Foundation (grant #  C. 90.1047).
References
Al-Awqati, Q., 1995, Regulation of ion channels by ABC transporters 
that secrete ATP, Science 269, 805.
Bernal, S.D., T.J. Lampidis, R.M. Mclsaac and L.B. Chen, 1983, Anticar- 
cinoma activity in vivo of rhodamine 123, a mitochondrial-specific 
dye, Science 222, 169.
Boom, S.P.A., F.W.J. Gribnau and F.G.M. Russel, 1992, Organic cation 
transport and cationic drug interactions in freshly isolated proximal 
tubular cells of the rat, J. Pharmacol. Exp. Ther. 263, 445.
Boom, S.P.A., M.M. Moons and F.G.M. Russel, 1994, Renal tubular 
transport of cimetidine in the isolated perfused kidney of the rat, Drug 
Metab. Dispos. 22, 148.
Brouty-Boye, D., D. Kolonias, C.J. Wu, N. Savaraj and T.J. Lampidis, 
1995, Relationship of multidrug resistance to rhodamine-123 selectiv­
ity between carcinoma and normal epithelial cells; taxol and vinblas­
tine modulate drug efflux, Cancer Res. 55, 1633.
Chan, L. and R.W. Schrier, 1990, Effects of calcium channel blockers on 
renal function, Annu. Rev. Med. 41, 289.
Cox, P.G.F., M.M. Moons, J.F.G. Siegers, FG.M. Russel and C.A.M. 
Van Ginneken, 1990, Isolated perfused rat kidney as a tool in the 
in vestigation of renal handling and effects of nonsteroidal antiinflam­
matory drugs, J. Pharmacol. Methods 24, 89.
De Lannoy, I,A.M., G. Koren, J. Klein, J. Charuk and M. Silverman, 
1992, Cyclosporin and quinidine inhibition of renal digoxin excretion: 
evidence for luminal secretion of digoxin, Am. J. Physiol. 263, F613.
Denis-Gay, M„ J.-M. Petit and M.-H. Ratinaud, 1995, Rhodamine 123: Is 
it an appropriate dye to study P-glycoprotein activity in adriamycin- 
resistant K562 cells? Anticancer Res. 15, 121.
Emaus, R.K., R. Grunwald and J.J. Lemasters, 1986, Rhodamine 123 as a 
probe of transmembrane potential in isolated rat-liver mitochondria: 
spectral and metabolic properties, Biochim. Biophys. Acta 850, 436.
Ford, J.M. and W.N. Halt, 1990, Pharmacology of drugs that alter 
multidrug resistance in cancer, Pharmacol. Rev. 42, 155.
Gottesman, M.M. and I. Pastan, 1993, Biochemistry of multidrug resis­
tance mediated by the multidrug transporter, Annu. Rev. Biochem. 
62, 385.
Heyrovski, A., 1956, A new method for the determination of inulin in 
plasma and urine, Clin. Chim, Acta 1, 470.
Holohan, P.D., K.E. White, P.P. Sokol and J. Rebbeor, 1992, Photoaffin- 
ity labeling of the organic c a t io n /H +  exchanger in renal brush 
border membrane vesicles, J. Biol. Chem. 267, 13513.
Hori, R., N. Okamura, T. Aiba and Y. Tanigawara, 1993, Role of 
P-glycoprotein in renal tubular secretion of digoxin in the isolated 
perfused rat kidney. J. Pharmacol. Exp. Ther. 266, 1620.
Hughes, C.M., J.G. Swanton and P.S. Collier, 1995, The effect of three 
H2 receptor antagonists on the disposition of cyclosporin A in the in 
situ perfused rat liver model, Biopharm. Drug Dispos. 16, 719,
Ichikawa-Haraguchi, M., T. Sumizawa, A. Yoshimura, T. Furukawa, S. 
Hiramoto, M, Sugita and S.-I. Akiyama, 1993, Progesterone and its 
metabolites: the potent inhibitors of the transporting activity of P~ 
glycoprotein in the adrenal gland, Biochim. Biophys. Acta 1158, 201.
Lampidis, T.J., S.D. Bernal, I.C. Summerhayes and L.B. Chen, 1983, 
Selective toxicity of rhodamine 123 in carcinoma cells in vitro, 
Cancer Res. 43, 716,
Lee, J.-S., K. Pauli, M. Alvarez, C. Hose, A. Monks, M. Grever, A.T, 
Fojo and S.E. Bates, 1994, Rhodamine efflux patterns predict P- 
glycoprotein substrates in the National Cancer Institute drug screen, J. 
Pharmacol. Exp. Ther. 46, 627.
Leveille-Webster, C.R. and I.M. Arias, 1995, The biology of P-glyco- 
proteins, J. Membr. Biol. 143, 89.
Lieberman, D.M., R.A.F. Reithmeier, V. Ling, J.H.M. Charuk, H. Gold­
berg and K.L. Skorecki, 1989, Identification of p-glycoprotein in 
renal brush border membranes, Biochem. Biophys. Res. Commun. 
162, 244.
Mellman, I., R. Fuchs and A. Helenius, 1986, Acidification of the 
endocytic and exocytic pathways, Annu. Rev. Biochem. 55, 663.
R. Masereeuw et a l /  European Journal o f Pharmacology 321 (1997) 315-323 323
Miller, D.S., 1995, Daunomycin secretion by killifish renal proximal 
tubules, Am. J. Physiol. 269, R370.
Nelson, J.A., A. Dutt, L.H. Allen and D.A. Wright, 1995, Functional 
expression of the renal organic cation transporter and P-glycoprotein 
in Xenopus laevis oocytes, Cancer Chemother. Pharmacol. 37, 187.
Neyfakh, A.A., A.S. Serpinskaya, A.V. Chervonsky, S.G. Apasov and 
A.R. Kazarov, 1989, Multidrug-resistance phenotype of a subpopula­
tion of T-lymphocytes without drug selection, Exp. Cell Res. 185, 
496.
Pan» B.-F., A. Dutt and J.A. Nelson, 1994, Enhanced transepithelial flux 
of cimetidine by Madin-Darby canine kidney cells overexpressing 
human p-glycoprotein, J. Pharmacol. Exp. Ther. 270, 1.
Pietruck, F. and K.J. Ullrich, 1995, Transport interactions of different 
organic cations during their excretion by the intact kidney, Kidney 
Int. 47, 1647.
Pritchard, J.B, and D.S. Miller, 1993, Mechanisms mediating renal 
secretion of organic anions and cations, Physiol, Rev. 73, 765.
Pritchard, J.B., D.B. Sykes, R. Walden and D.S. Miller, 1994, ATP-de- 
pendent transport of tetraethylammonium by endosomes isolated from 
rat renal cortex, Am. J. Physiol. 266, F966.
Saeki, T„ K. Ueda, Y. Tanigawara, R. Hori and T. Komano, 1993, 
Human P-glycoprotein transports cyclosporin A and FK506, J. Biol. 
Chem. 268, 6077.
Somogoyi, A., 1987, New insights into the renal secretion of drugs, 
Trends Pharmacol. Sci. 8, 354.
Stapf, V., T. Thalhammer, R. Huber-Huber, F. Felberbauer, L. Gajdzik 
and J. Graf, 1994, Inhibition of rhodamine 123 secretion by cy­
closporin A as a model of P-glycoprotein mediated transport in liver, 
Anticancer Res. 14, 581.
Thibaut, F., T. Tsuruo, H. Hamada, M.M. Gottesman, I. Pastan and M.C, 
Willingham, 1987, Cellular localization of the multidrug resistance 
gene product P-glycoprotein in normal human tissues, Proc. Natl. 
Acad. Sci. USA 84, 7735.
Ueda, fC, N. Okamura, M. Hirai, Y. Tanigawara, T. Saeki, N. Kioka, T. 
Komano and R. Hori, 1992, Human P-glycoprotein transports cortisol, 
aldosterone, and dexamethasone, but not progesterone, J. Biol. Chem.
267, 24248.
